Spyre Therapeutics Inc. (SYRE) exhibits 44.0% gross margins and -20.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 6.5% implied options volatility.
Sustained 44.0% gross profitability converts into 16.5% operating margin and -20.0% ROIC, outpacing sector cost of capital.
ROIC: -20.0% // GM: 44.0%YoY revenue trajectory of +17.6% paired with -1.64% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +17.6% // FCF YLD: -1.64%Altman Z-Score of 26.00 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 26.00 // F-SCORE: 5/9Trading at 24.0x trailing P/E (22.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±6.5% implied move with a 0.93 put/call ratio around $97.00 max pain.
IMPL MOVE: ±6.5% // P/C: 0.93Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 12.4% net margins.
NET MARGIN: 12.4% // D/E: 0.04x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for SYRE & activate live FRED threshold breach alerts.